Boltz raises $110M Series A for AI biomolecular design, partners with 6 top-20 pharma giants
GabriCorso · x · 2026-11-18
Boltz has raised a $110M Series A led by Bessemer VP, following 50x growth in molecular token usage since June. Its partners include Pfizer, GSK, Takeda and BMS — 6 of the world's 20 largest pharma companies.
The team's long-term goal: a scientist goes from therapeutic hypothesis to human-ready molecule entirely on a computer. BoltzMol-1 and BoltzProt-1 (released in June) took a key step toward reliable small-molecule hit discovery and protein binder design for hard targets; next-gen models already show substantial quality gains, and the funding goes into compute, data and team.
More from Venture
- Perplexity CEO Reveals $1B ARR With Strong Margins and Healthy Growth — inductionheads · 2026-11-18
- SEO consultant pitches 14 journalists a week, calls GEO "BS" — gaganghotra_ · 2026-11-18
- Boltz's long-term goal: hypothesis to human-ready molecule without leaving the computer — GabriCorso · 2026-11-18
- Boltz Lab now a daily tool for pharma scientists; partners include Pfizer, GSK, Takeda, BMS — GabriCorso · 2026-11-18
- Anthropic IPO: $70-78/share, up to ~$1.4T valuation, ~$90B raise with supplier private placement — RihardJarc · 2026-11-18
- Traders Buy Anthropic at $1.8T Valuation on Pre-IPO Perps, Calling It a No-Brainer — adamamcbride · 2026-11-18